Antibodies Neutralizing Soluble CD39 Enzymatic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies fail to effectively inhibit the enzymatic activity of soluble human CD39, a key player in immunosuppression and tumor growth, as they do not target the soluble extracellular form of the protein, which is distinct from the membrane-bound form.
Innovation Solution
Development of antibodies that specifically bind to and neutralize both the soluble and membrane-bound forms of human CD39, inhibiting its ATPase activity, thereby reducing immunosuppression and potentially treating cancer and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to target CD39, then membrane-bound CD39 may be inhibited, but soluble CD39 enzymatic activity is not inhibited
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure and binding characteristics to achieve inhibition of soluble CD39 enzymatic activity. The developed antibodies have specific binding parameters that allow them to recognize and inhibit the extracellular domain of soluble CD39, unlike conventional antibodies that only target membrane-bound forms. This involves optimizing affinity, epitope recognition, and binding kinetics to effectively neutralize soluble CD39 while maintaining or enhancing overall CD39 inhibition capability.
2Reliability
If small molecule inhibitors like ARL67156 are used, then CD39 active site is inhibited, but other NTPDases are also inhibited and specificity is reduced
Solution Approach 1:
The patent uses antibodies as intermediary molecules that specifically recognize and bind to the extracellular domain of soluble CD39. These antibodies act as selective mediators that inhibit CD39 enzymatic activity without affecting other NTPDases. The antibody-antigen interaction provides high specificity through complementary binding to unique epitopes on soluble CD39, avoiding the off-target effects seen with small molecule inhibitors that bind to conserved active site regions shared by multiple NTPDases.
Solution Approach 2:
The patent applies local quality by designing antibodies that target specific local regions (epitopes) on the soluble CD39 extracellular domain. Rather than binding to the conserved active site that is shared across multiple NTPDases, the antibodies recognize unique local structural features of soluble CD39. This localized binding approach ensures high specificity for CD39 while preserving the function of other NTPDase enzymes.
3Adaptability or versatility
If antibodies with effector function are used, then FcγR binding occurs, but blocking activity is reduced
Solution Approach 1:
The patent applies dynamics by creating antibody variants with adjustable Fc region properties. The antibodies can be engineered to have different FcγR binding characteristics while maintaining or enhancing CD39 blocking activity. This dynamic approach allows optimization of both effector function and enzymatic inhibition by adjusting the balance between Fc region engagement and Fab region binding to soluble CD39, enabling flexible tuning of therapeutic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies achieve significant neutralization of CD39 activity in both forms, leading to reduced immunosuppression and enhanced immune function, with potential therapeutic benefits in cancer treatment by decreasing adenosine levels in the tumor microenvironment.
Implementation Method 1
antibodies that inhibit the enzymatic activity of soluble human CD39... inhibit the ATPase activity of soluble extracellular CD39 protein
Implementation Method 2
The antibodies can be used advantageously to achieve greater neutralization of CD39 activity in an individual by neutralizing both membrane-bound and soluble CD39 protein
Data Source
AI summary
The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.